×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NYSEAMERICAN:PLX

Protalix BioTherapeutics Stock Forecast, Price & News

$1.09
-0.01 (-0.91%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.08
$1.13
50-Day Range
N/A
52-Week Range
$0.70
$2.07
Volume
137,073 shs
Average Volume
2.13 million shs
Market Capitalization
$51.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive PLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

PLX Stock Forecast (MarketRank)

Overall MarketRank

1.31 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
Protalix BioTherapeutics logo

About Protalix BioTherapeutics (NYSEAMERICAN:PLX)

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

PLX Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:PLX
Previous Symbol
NYSEMKT:PLX
Employees
202
Year Founded
N/A

Company Calendar

Last Earnings
3/31/2022
Today
6/24/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

Profitability

Net Income
$-6.52 million
Pretax Margin
-41.62%

Debt

Sales & Book Value

Annual Sales
$62.90 million
Book Value
($0.81) per share

Miscellaneous

Free Float
44,067,000
Market Cap
$51.30 million
Optionable
Optionable
Beta
2.19














Protalix BioTherapeutics Frequently Asked Questions

Are investors shorting Protalix BioTherapeutics?

Protalix BioTherapeutics saw a decrease in short interest in May. As of May 31st, there was short interest totaling 2,740,000 shares, a decrease of 27.7% from the May 15th total of 3,790,000 shares. Based on an average trading volume of 3,700,000 shares, the short-interest ratio is presently 0.7 days. Approximately 7.2% of the company's shares are sold short.
View Protalix BioTherapeutics' Short Interest
.

When is Protalix BioTherapeutics' next earnings date?

Protalix BioTherapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Protalix BioTherapeutics
.

How were Protalix BioTherapeutics' earnings last quarter?

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) issued its quarterly earnings data on Thursday, March, 31st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.03. The company earned $8.55 million during the quarter, compared to analysts' expectations of $7.79 million.
View Protalix BioTherapeutics' earnings history
.

When did Protalix BioTherapeutics' stock split? How did Protalix BioTherapeutics' stock split work?

Protalix BioTherapeutics shares reverse split on Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 19th 2019. An investor that had 100 shares of Protalix BioTherapeutics stock prior to the reverse split would have 10 shares after the split.

Who are Protalix BioTherapeutics' key executives?

Protalix BioTherapeutics' management team includes the following people:
  • Mr. Dror Bashan, Pres, CEO & Director (Age 55, Pay $490.1k)
  • Mr. Eyal Rubin M.B.A., Sr. VP, CFO, Treasurer & Corp. Sec. (Age 46, Pay $430.56k)
  • Dr. Einat Brill-Almon Ph.D., Sr. VP & Chief Devel. Officer (Age 62, Pay $430.98k)
  • Mr. Yaron Naos, Sr. VP of Operations (Age 58)
  • Ms. Dafna Shelly M.Sc., MBA, VP of HR

What other stocks do shareholders of Protalix BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protalix BioTherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Pluristem Therapeutics (PSTI), Novavax (NVAX), BioLineRx (BLRX), VBI Vaccines (VBIV), Sangamo Therapeutics (SGMO), Verastem (VSTM), OPKO Health (OPK), Sorrento Therapeutics (SRNE) and CRISPR Therapeutics (CRSP).

What is Protalix BioTherapeutics' stock symbol?

Protalix BioTherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."

Who are Protalix BioTherapeutics' major shareholders?

Protalix BioTherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Meitav Dash Investments Ltd. (0.53%), Spire Wealth Management (0.32%), Jane Street Group LLC (0.31%), Group One Trading L.P. (0.00%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). Company insiders that own Protalix BioTherapeutics stock include Aharon Schwartz, Dror Bashan and Pharma Technologies Ltd Dexcel.
View institutional ownership trends for Protalix BioTherapeutics
.

Which major investors are selling Protalix BioTherapeutics stock?

PLX stock was sold by a variety of institutional investors in the last quarter, including Group One Trading L.P., and Simplex Trading LLC.
View insider buying and selling activity for Protalix BioTherapeutics
or view top insider-selling stocks.

Which major investors are buying Protalix BioTherapeutics stock?

PLX stock was purchased by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd., Jane Street Group LLC, and Spire Wealth Management.
View insider buying and selling activity for Protalix BioTherapeutics
or or view top insider-buying stocks.

How do I buy shares of Protalix BioTherapeutics?

Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protalix BioTherapeutics' stock price today?

One share of PLX stock can currently be purchased for approximately $1.09.

How much money does Protalix BioTherapeutics make?

Protalix BioTherapeutics (NYSEAMERICAN:PLX) has a market capitalization of $51.30 million and generates $62.90 million in revenue each year. The company earns $-6.52 million in net income (profit) each year or ($0.450010) on an earnings per share basis.

How many employees does Protalix BioTherapeutics have?

Protalix BioTherapeutics employs 202 workers across the globe.

How can I contact Protalix BioTherapeutics?

Protalix BioTherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The official website for Protalix BioTherapeutics is www.protalix.com. The company can be reached via phone at (201) 696-9345, via email at [email protected], or via fax at 972-4988-9489.

This page (NYSEAMERICAN:PLX) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.